Method for detecting molecules that inhibit the interaction of cd36 protein with amyloid beta
AssigneeInstituto de Investigaciones Cientificas y Servicios de Alto Technologia AIP (Indicasat AIP)
InventorsPatricia LLANES FERNANDEZ, Ricardo LLEONART CRUZ, Deborah Doens
Life of this patent
Estimating the term…
Abstract
Disclosed is a method for identifying inhibitors of the interaction of CD36 receptor and amyloid-beta protein (Aβ), which consists in: immobilizing CD36 on a polystyrene plate; and detecting by colorimetric, the interaction thereof with fibrillar Aβ (fAβ), using a polyclonal anti-Aβ antibody and a secondary antibody conjugated to horseradish peroxidase (HRP). The inhibitors identified are potential agents for the treatment of Alzheimer's disease.
Claims14
A method for detecting a molecule that inhibits CD36-amyloid beta (Aβ) peptide interactions in an assay, the method comprising:
- (i) immobilizing the CD36 on a solid surface of the assay;
- (ii) adding the Aβ peptide in its fibril state and a candidate inhibitor molecule to the soluble phase of the assay;
- (iii) adding a primary antibody specific for a CD36-Aβ complex, and a secondary antibody labeled with a marker molecule that recognizes the primary antibody;
- (iv) adding a substrate that produces a colorimetric signal in the presence of the CD36-Aβ complex;
- and
- (v) detecting the presence of the colorimetric signal,
- wherein a reduction or absence of a colorimetric signal is indicative that the candidate molecule is an inhibitor of CD36-Aβ interactions.
A method for detecting a molecule that inhibits CD36-amyloid beta (Aβ) peptide interactions in an assay, the method comprising:
- (i) immobilizing the Aβ peptide on a solid surface of the assay;
- (ii) adding the CD36 and a candidate inhibitor molecule to the soluble phase of the assay, wherein said CD36 is a recombinant peptide corresponding to the extracellular portion of CD36;
- (iii) adding a primary antibody specific for a CD36-Aβ complex, and a secondary antibody labeled with a marker molecule that recognizes the primary antibody;
- (iv) adding a substrate that produces a colorimetric signal in the presence of the CD36-Aβ complex;
- and
- (v) detecting the presence of the colorimetric signal,
- wherein a reduction or absence of a colorimetric signal is indicative that the candidate molecule is an inhibitor of CD36-Aβ interactions.
Dependencies are inferred from the claim text.